REG - AstraZeneca PLC - Ultomiris recommended for EU approval for gMG

AstraZenecaAnnouncement

25/07/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220725:nRSY5248Ta&default-theme=true

RNS Number : 5248T  AstraZeneca PLC  25 July 2022

25 July 07:05 BST

 

Ultomiris recommended for approval in the EU by CHMP for the treatment of
adults with generalised myasthenia gravis

 

First and only long-acting C5 complement inhibitor showed early effect and
demonstrated clinical improvement in activities of daily living

 

Ultomiris (ravulizumab) has been recommended for marketing authorisation in
the European Union (EU) as an add-on to standard therapy for the treatment of
adult patients with generalised myasthenia gravis (gMG) who are
anti-acetylcholine receptor (AChR) antibody-positive. If authorised, Ultomiris
would be the first and only approved long-acting C5 complement inhibitor for
the treatment of AChR antibody-positive gMG in the EU.

 

The Committee for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency based its positive opinion on results from the CHAMPION-MG
Phase III trial.

 

In this trial, Ultomiris was superior to placebo in the primary endpoint of
change from baseline in the Myasthenia Gravis-Activities of Daily Living
Profile (MG-ADL) total score at Week 26, a patient-reported scale that
assesses patients' abilities to perform daily activities.(1)

 

gMG is a rare, debilitating, chronic, autoimmune neuromuscular disease that
leads to a loss of muscle function and severe weakness.(2) The diagnosed
prevalence of gMG in the EU is estimated at approximately 89,000.(3-9)

 

Renato Mantegazza, Professor at the Department of Neuroimmunology and
Neuromuscular Diseases, Fondazione IRCCS Istituto Neurologico Carlo Besta,
Milan, Italy, and CHAMPION-MG trial investigator, said: "gMG is a rare and
complex disorder that requires early, consistent and reliable intervention.
This positive recommendation offers hope to the community for an effective
long-acting option that will require fewer treatments each year and help
improve disease management."

 

Marc Dunoyer, Chief Executive Officer, Alexion, said: "This recommendation is
a major milestone in our commitment to help a broader range of
gMG patients, including those with milder symptoms, and expand access to
Ultomiris. As we listen to the patient community, we're focused on
understanding and meeting the needs of gMG patients, providing them with
effective and accessible treatment options, and the positive opinion is a
great step forward."

 

In CHAMPION-MG, the safety profile of Ultomiris was comparable to placebo
and consistent with that observed in Phase III trials of Ultomiris in
paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic
syndrome (aHUS). The most common adverse drug reactions are diarrhoea, upper
respiratory tract infection, nasopharyngitis and headache.(1)

The CHMP recommended approval as an add-on to standard therapy for the
treatment of adult patients with gMG who are AChR antibody-positive.

 

Ultomiris was approved in the US
(https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-approved-in-the-us-for-adults-with-generalised-myasthenia-gravis.html)
for adults with gMG who are AChR antibody-positive in April 2022, and
regulatory reviews are ongoing in additional countries, including Japan.

 

Notes

 

gMG

gMG is a rare autoimmune disorder characterised by loss of muscle function and
severe muscle weakness.(2)

 

Eighty percent of people with gMG are AChR antibody positive meaning they
produce specific antibodies (anti-AChR) that bind to signal receptors at the
neuromuscular junction (NMJ), the connection point between nerve cells and the
muscles they control.(2,4,5,10,11) This binding activates the complement
system, which is essential to the body's defence against infection, causing
the immune system to attack the NMJ.(2) This leads to inflammation and a
breakdown in communication between the brain and the muscles.(2)

 

gMG can occur at any age, but it most commonly begins for women before the age
of 40 and for men after the age of 60.(12-14) Initial symptoms may include
slurred speech, double vision, droopy eyelids and lack of balance; these can
often lead to more severe symptoms as the disease progresses such as, impaired
swallowing, choking, extreme fatigue and respiratory failure.(15,16)

 

CHAMPION-MG

The global Phase III randomised, double-blind, placebo-controlled, multicentre
26-week trial evaluated the safety and efficacy of Ultomiris in adults with
gMG. The trial enrolled 175 patients across North America, Europe,
Asia-Pacific and Japan. Participants were required to have a confirmed
myasthenia gravis diagnosis at least six months prior to the screening visit
with a positive serologic test for anti-AChR antibodies, MG-ADL total score of
at least 6 at trial entry and Myasthenia Gravis Foundation of America Clinical
Classification Class II to IV at screening. Patients could stay on stable
standard of care medicines, with a few exceptions, for the duration of the
randomised control period.(17)

 

Patients were randomised 1:1 to receive Ultomiris or placebo for a total of 26
weeks. Patients received a single weight-based loading dose on Day 1, followed
by regular weight-based maintenance dosing beginning on Day 15, every eight
weeks. The primary endpoint of change from baseline in the MG-ADL total score
at Week 26 was assessed along with multiple secondary endpoints evaluating
improvement in disease-related and quality-of-life measures.

 

Patients who completed the randomised control period were eligible to continue
into an open-label extension period evaluating the safety and efficacy of
Ultomiris, which is ongoing.

 

Ultomiris

Ultomiris (ravulizumab), the first and only long-acting C5 complement
inhibitor, offers immediate, complete and sustained complement inhibition. The
medication works by inhibiting the C5 protein in the terminal complement
cascade, a part of the body's immune system. When activated in an uncontrolled
manner, the complement cascade over-responds, leading the body to attack its
own healthy cells. Ultomiris is administered intravenously every eight weeks
in adult patients, following a loading dose.

 

Ultomiris is approved in the US for the treatment of certain adults with gMG.

 

Ultomiris is also approved in the US, EU and Japan for the treatment of
certain adults and children with PNH.

 

Additionally, Ultomiris is approved in the US, EU and Japan for certain adults
and children with aHUS to inhibit complement-mediated thrombotic
microangiopathy.

 

As part of a broad development programme, Ultomiris is being assessed for the
treatment of additional haematology and neurology indications.

 

Alexion

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on
rare diseases, created following the 2021 acquisition of Alexion
Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is
focused on serving patients and families affected by rare diseases and
devastating conditions through the discovery, development and
commercialisation of life-changing medicines. Alexion focuses its research
efforts on novel molecules and targets in the complement cascade and its
development efforts on haematology, nephrology, neurology, metabolic
disorders, cardiology and ophthalmology. Headquartered in Boston,
Massachusetts, Alexion has offices around the globe and serves patients in
more than 50 countries.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

References

1.   Ultomiris (ravulizumab-cwvz) US prescribing information; 2022.

2.   Howard, J. F., (2017). Myasthenia gravis: the role of complement at the
neuromuscular junction. Annals of The New York Academy of Sciences, 1412(1),
113-128.

3.   Westerberg E, Punga AR. Epidemiology of Myasthenia Gravis in Sweden
2006-2016. Brain Behav. 2020;10:e01819. https://doi.org/10.1002/brb3.1819

4.   Anil, R., Kumar, A., Alaparthi, S., Sharma, A., Nye, JL., Roy, B.,
O'Connor, KC., Nowak, R., (2020). Exploring outcomes and characteristics of
myasthenia gravis: Rationale, aims and design of registry - The EXPLORE-MG
registry. J Neurol Sci. 2020 Jul 15;414:116830.

5.   Oh SJ., (2009). Muscle-specific receptor tyrosine kinase antibody
positive myasthenia gravis current status. Journal of Clinical Neurology.
2009b Jun 1;5(2):53-64.

6.   Fang, F., Sveinsson O., Thormar G., Granqvist M., Askling J., Lundberg
IE., Ye W., (2015). The autoimmune spectrum of myasthenia gravis: a Swedish
population-based study. J Intern Med 2015; 277:594-604.

7.   Lefter, S., Hardiman, O., Ryan, A., (2017). A population-based
epidemiologic study of adult neuromuscular disease in the Republic of Ireland.
Neurology 2017;88:304-313.

8.   Pallaver, F., Riviera, AP., Piffer, S., Ricciardi, R., Roni, R.,
Orrico, D., Bonifati, DM., (2011). Change in Myasthenia Gravis Epidemiology in
Trento, Italy, after Twenty Years. Neuroepidemiology 2011;36:282-287.

9.   Santos, E., Coutinho, E., Moreira, I., et.al., (2016). Epidemiology of
Myasthenia Gravis in Northern Portugal: Frequency Estimates and Clinical
Epidemiological Distribution of Cases. Muscle Nerve 2016; 54: 413-421.

10.  Tomschik, M., Hilger, E., Rath, J., Mayer, EM., Fahrner, M., Cetin, H.,
Löscher, W., Zimprich, F., (2020). Subgroup stratification and outcome in
recently diagnosed generalized myasthenia gravis. Neurology. 2020 Sep
8;95(10):e1426-e1436.

11.  Hendricks, TM., Bhatti, MT., Hodge, D., Chen, J., (2019). Incidence,
Epidemiology, and Transformation of Ocular Myasthenia Gravis: A
Population-Based Study. Am J Ophthalmol. 2019 Sep;205:99-105.

12.  Myasthenia Gravis. National Organization for Rare Disorders (NORD).
Available here (https://rarediseases.org/rare-diseases/myasthenia-gravis/) .
Accessed March 2022.

13.  Howard, J. F., (2015). Clinical Overview of MG. Available here
(https://myasthenia.org/Professionals/Clinical-Overview-of-MG) . Accessed
March 2022.

14.  Sanders, D. B., Raja, S. M., Guptill J. T., Hobson-Webb, L. D., Juel, V.
C., & Massey, J. M., (2020). The Duke myasthenia gravis clinic registry:
I. Description and demographics. Muscle & Nerve, 63(2), 209-216.

15.  Myasthenia Gravis Fact Sheet. (2020, April 27). National Institutes of
Neurological Disorders and Stroke. Available here
(https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Myasthenia-Gravis-Fact-Sheet)
. Accessed March 2022.

16.  Ding, J., Zhao, S., Ren, K., Dang, D., Li, H., Wu, F., Zhang, M., Li,
Z., & Guo, J., (2020). Prediction of generalization of ocular myasthenia
gravis under immunosuppressive therapy in Northwest China. BMC Neurology,
20(238).

17.  ClinicalTrials.gov. Safety and Efficacy Study of Ravulizumab in Adults
With Generalized Myasthenia Gravis. NCT Identifier: NCT03920293. Available
here (https://clinicaltrials.gov/ct2/show/NCT03920293) . Accessed March 2022.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCRIMATMTBTBBT